- For Users
- For Industry
- News & Events
- Staff Directory
Fine Tuning Drugs to Fight Cancer
Scientists reveal, for the first time, how the drug Trametinib binds itself to its target
November 30, 2020
The schematic shows the Trametinib-binding pocket of Methyl Ethyl Ketone (MEK) (pink) and KSR (cyan). Image credit: Z. M. Khan. Nature 588, 509–514(2020)
Scientists reveal the first co-crystal structures of the clinical Methyl Ethyl Ketone (MEK) inhibitor, Trametinib, and find that the drug binds at the interface of MEK and its scaffold protein Kinase Suppressor of RAS (KSR).
Although Trametinib is used to treat melanoma, its mechanism of action was not fully understood; this work reveals how the drug binds to its target.
A broad range of cancers, including pancreatic, skin, and colorectal cancer, are driven by abnormal activity in the mitogen activation protein kinase network and are linked to frequent mutations in K-RAS and B-RAF. Trametinib is a promising cancer drug that binds to MEK and is currently FDA-approved for the treatment of BRAF V600E/K mutant melanoma; however, how Trametinib works and why this drug shows differential activity to other MEK inhibitors has been a mystery.
In this work, scientists from the Arvin Dar Laboratory at the Tisch Cancer Institute in the Icahn School of Medicine at Mount Sinai, New York determined the first ever co-crystal structures of Trametinib, revealing an unexpected mode of action whereby the drug spans the interface of an important regulatory complex in the RAS pathway.
Using crystallographic, biochemistry, and cell biology analysis the team found that Trametinib simultaneously binds to MEK and its cellular partner KSR. Further, based on these insights, the Dar laboratory designed a novel compound, which they dubbed ‘Trametiglue’, to overcome a common drug resistance mechanism that limits the efficacy of MEK inhibitors as cancer therapeutics.
This work reveals a novel strategy for designing compounds that bind at the interface of protein-protein complexes, which holds great potential for many challenging drug targets.
For this study the X-ray diffraction data were collected at the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines at the National Synchrotron Light Source II (NSLS-II). NSLS-II is a U.S. Department of Energy (DOE) Office of Science User Facility located at DOE’s Brookhaven National Laboratory and offers access to state-of-the-art materials characterization and life science tools for researchers from industry and academia. Crystallography data were also collected at the LS-CAT beamline at the Advanced Photon Source at Argonne National Laboratory.
Arvin C. Dar
Icahn School of Medicine at Mount Sinai
Z. M. Khan, A. M. Real, W. M. Marsiglia, A. Chow, M. E. Duffy, J. R. Yerabolu, A. P. Scopton, A. C. Dar. Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature 588, 509–514(2020). DOI 10.1038/s41586-020-2760-4
The Dar laboratory has been supported by innovation awards from the NIH (1DP2CA186570-01) and Damon Runyan Rachleff Foundation, as well as NIH grants 1RO1CA227636 and 5U54OD020353. The authors are also supported by NCI grant P30 CA196521 to the Tisch Cancer Institute. A.M.R. and W.M.M. are recipients of NIH F30 (CA232454) and F99/K00 (CA212474) awards, respectively. A.C. and M.E.D. are recipients of T32 fellowships 5T32CA078207 and 5T32GM062754, respectively. A.C.D. has been supported as a Pew-Stewart Scholar in Cancer Research and a Young Investigator of the Pershing-Square Sohn Cancer Research Alliance.
2020-18791 | INT/EXT | Newsroom